Helmy Eltoukhy Sells 100,000 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) CEO Helmy Eltoukhy sold 100,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $126.30, for a total value of $12,630,000.00. Following the completion of the sale, the chief executive officer directly owned 2,012,919 shares in the company, valued at approximately $254,231,669.70. This represents a 4.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Guardant Health Stock Performance

Shares of NASDAQ:GH traded down $0.72 during midday trading on Monday, hitting $124.89. The company’s stock had a trading volume of 2,213,881 shares, compared to its average volume of 2,140,162. Guardant Health, Inc. has a fifty-two week low of $40.35 and a fifty-two week high of $134.28. The stock’s 50 day simple moving average is $99.39 and its 200 day simple moving average is $101.12. The stock has a market capitalization of $16.56 billion, a price-to-earnings ratio of -36.84 and a beta of 1.61.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. V Square Quantitative Management LLC bought a new position in shares of Guardant Health in the fourth quarter valued at about $27,000. Chesapeake Asset Management LLC acquired a new stake in Guardant Health in the 4th quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Guardant Health in the fourth quarter worth about $31,000. Elyxium Wealth LLC acquired a new position in shares of Guardant Health during the fourth quarter worth approximately $35,000. Finally, Parallel Advisors LLC lifted its position in shares of Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on GH shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research report on Tuesday, April 21st. Canaccord Genuity Group boosted their price target on Guardant Health from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, February 20th. BTIG Research set a $160.00 price target on Guardant Health and gave the company a “buy” rating in a report on Wednesday, May 27th. Citigroup raised their price objective on Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Finally, Robert W. Baird assumed coverage on Guardant Health in a report on Tuesday, February 17th. They set an “outperform” rating and a $120.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $139.80.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.